Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
Sumanta Kumar Pal, MD
Advertisement
Articles by Sumanta Kumar Pal, MD
Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.
Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.
Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.
Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.
Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.
Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.
Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).
Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses developments made in frontline treatment for patients with metastatic renal cell carcinoma (mRCC).
Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the frontline approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.
Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.
Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.
Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.
Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.
Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).
Advertisement
Latest Updated Articles
Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCCPublished: October 1st 2020 | Updated:
Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCCPublished: September 10th 2020 | Updated:
Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCCPublished: September 15th 2020 | Updated:
Dr. Pal on Biomarker Development in Renal Cell CarcinomaPublished: July 15th 2016 | Updated:
Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCCPublished: November 3rd 2016 | Updated:
Dr. Pal on Preoperative Immunotherapy in Patients With RCCPublished: January 24th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5